172 related articles for article (PubMed ID: 33287897)
21. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
22. Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
Stelloo E; Jansen AML; Osse EM; Nout RA; Creutzberg CL; Ruano D; Church DN; Morreau H; Smit VTHBM; van Wezel T; Bosse T
Ann Oncol; 2017 Jan; 28(1):96-102. PubMed ID: 27742654
[TBL] [Abstract][Full Text] [Related]
23. MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.
Fraune C; Burandt E; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Höflmayer D; Blessin NC; Mandelkow T; Li W; Perez D; Izbicki JR; Wilczak W; Sauter G; Schrader J; Neipp M; Mofid H; Daniels T; Isbert C; Clauditz TS; Steurer S
Ann Surg Oncol; 2020 Oct; 27(10):3997-4006. PubMed ID: 32108923
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
25. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
26. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.
Mead LJ; Jenkins MA; Young J; Royce SG; Smith L; St John DJ; Macrae F; Giles GG; Hopper JL; Southey MC
Clin Cancer Res; 2007 May; 13(10):2865-9. PubMed ID: 17504984
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
29. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract][Full Text] [Related]
30. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
31. Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability.
Kets CM; van Krieken JH; Hebeda KM; Wezenberg SJ; Goossens M; Brunner HG; Ligtenberg MJ; Hoogerbrugge N
Br J Cancer; 2006 Dec; 95(12):1678-82. PubMed ID: 17117178
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
34. Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer.
Jin HY; Liu X; Li VK; Ding Y; Yang B; Geng J; Lai R; Ding S; Ni M; Zhao R
BMC Cancer; 2008 Feb; 8():44. PubMed ID: 18257912
[TBL] [Abstract][Full Text] [Related]
35. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma.
Ahmad-Nielsen SA; Bruun Nielsen MF; Mortensen MB; Detlefsen S
Pathol Res Pract; 2020 Jun; 216(6):152985. PubMed ID: 32360245
[TBL] [Abstract][Full Text] [Related]
36. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
38. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications.
Schneider B; Glass Ä; Jagdmann S; Hühns M; Claus J; Zettl H; Dräger DL; Maruschke M; Hakenberg OW; Erbersdobler A; Zimpfer A
Clin Genitourin Cancer; 2020 Oct; 18(5):e563-e572. PubMed ID: 32340874
[TBL] [Abstract][Full Text] [Related]
39. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
